 <h1>Hydroxychloroquine Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to hydroxychloroquine: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, hydroxychloroquine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking hydroxychloroquine:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, loosening of the skin</li>
<li>blurred vision or other vision changes</li>
<li>chest discomfort, pain, or tightness</li>
<li>cough or hoarseness</li>
<li>dark urine</li>
<li>decreased urination</li>
<li>defective color vision</li>
<li>diarrhea</li>
<li>difficulty breathing</li>
<li>difficulty seeing at night</li>
<li>dizziness or fainting</li>
<li>fast, pounding, uneven heartbeat</li>
<li>feeling that others are watching you or controlling your behavior</li>
<li>feeling that others can hear your thoughts</li>
<li>feeling, seeing, or hearing things that are not there</li>
<li>fever with or without chills</li>
<li>general feeling of tiredness or weakness</li>
<li>headache</li>
<li>inability to move the eyes</li>
<li>increased blinking or spasms of the eyelid</li>
<li>joint or muscle pain</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, and sex organs</li>
<li>loss of hearing</li>
<li>lower back or side pain</li>
<li>noisy breathing</li>
<li>painful or difficult urination</li>
<li>red irritated eyes</li>
<li>red skin lesions, often with a purple center</li>
<li>severe mood or mental changes</li>
<li>sore throat sores, ulcers, or white spots on the lips or in the mouth</li>
<li>sticking out of the tongue</li>
<li>stomach pain</li>
<li>swelling of the feet or lower legs</li>
<li>swollen or painful glands</li>
<li>trouble with breathing, speaking, or swallowing</li>
<li>uncontrolled twisting movements of the neck, trunk, arms, or legs</li>
<li>unusual behavior</li>
<li>unusual bleeding or bruising</li>
<li>unusual facial expressions</li>
<li>unusual tiredness or weakness</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Drowsiness</li>
<li>dry mouth</li>
<li>increased thirst</li>
<li>loss of appetite</li>
<li>mood changes</li>
<li>no pulse or blood pressure</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>unconsciousness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of hydroxychloroquine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Continuing ringing or buzzing or other unexplained noise in the ears</li>
<li>feeling of constant movement of self or surroundings</li>
<li>irritability</li>
<li>nausea</li>
<li>nervousness</li>
<li>nightmares</li>
<li>sensation of spinning</li>
<li>shakiness and unsteady walk</li>
<li>uncontrolled eye movements</li>
<li>unsteadiness, trembling, or other problems with muscle control or coordination</li>
<li>vomiting</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to hydroxychloroquine: compounding powder, oral tablet</i></p><h3>Cardiovascular</h3><p>QT interval prolongation has been reported in patients with specific risk factors, which may lead to arrhythmia (torsade de pointes, ventricular tachycardia).<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Cardiomyopathy (sometimes resulting in cardiac failure; some with fatal outcome), conduction disorders (bundle branch block/atrioventricular heart block), biventricular hypertrophy</p>
<p><b>Frequency not reported</b>: Arrhythmia (torsade de pointes, ventricular tachycardia)</p>
<p><b>Postmarketing reports</b>: QT interval prolongation, ventricular arrhythmias, torsade de pointes<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision (including due to disturbance of accommodation)</p>
<p><b>Uncommon</b> (0.1% to 1%): Retinopathy (with changes in pigmentation, visual field defects), retinal changes (including paracentral, pericentral ring types, temporal scotomas, abnormal color vision), corneal changes (including edema, opacities), haloes, photophobia</p>
<p><b>Very rare</b> (less than 0.01%): Extraocular muscle palsies</p>
<p><b>Frequency not reported</b>: Maculopathies, macular degeneration, abnormal macular pigmentation and depigmentation (sometimes with bull's eye appearance), pallor of optic disc, optic atrophy, narrowing of retinal arterioles</p>
<p><b>Postmarketing reports</b>: Irreversible retinopathy with retinal pigmentation changes (bull's eye appearance), visual field defects (paracentral scotomas), visual disturbances (visual acuity), maculopathies (macular degeneration), decreased dark adaptation, color vision abnormalities, corneal changes (edema, opacities), corneal deposition of drug with or without accompanying symptoms (halo around lights, photophobia, blurred vision<sup>[Ref]</sup></p><p>Blurred vision (temporary) and extraocular muscle palsies (reversible) were due to disturbance of accommodation, which was dose dependent and reversible.</p>
<p></p>
<p>Retinopathy appeared to be uncommon when the recommended daily dose was not exceeded.  In its early form, it appeared reversible when therapy was discontinued.  If allowed to develop, there was risk of progression even after treatment withdrawal.</p>
<p></p>
<p>Patients with retinal changes were asymptomatic initially or had scotomatous vision with paracentral, pericentral ring types, temporal scotomas, and abnormal color vision.</p>
<p></p>
<p>Corneal changes (including edema and opacities) have occurred from 3 weeks (infrequently) to some years after starting therapy.  They were either symptomless or caused disturbances such as haloes, blurred vision, or photophobia; they may be transient and were reversible when therapy was discontinued.</p>
<p></p>
<p>Maculopathies and macular degeneration have been reported (onset ranging from 3 months to several years of exposure to this drug) and may be irreversible.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain, nausea</p>
<p><b>Common</b> (1% to 10%): Diarrhea, vomiting<sup>[Ref]</sup></p><p>In general, abdominal pain, nausea, diarrhea, and vomiting resolved immediately when the dose was reduced or therapy was stopped.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>In general, skin rash, pruritus, pigmentation disorders in skin and mucous membranes, bleaching of hair, and alopecia resolved readily when therapy was discontinued.</p>
<p></p>
<p>AGEP had to be distinguished from psoriasis, although this drug has precipitated attacks of psoriasis.  AGEP has been associated with fever and hyperleukocytosis.  In general, outcome was favorable after stopping this drug.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Skin rash, pruritus, alopecia</p>
<p><b>Uncommon</b> (0.1% to 1%): Pigmentary changes, pigmentation disorders in skin and mucous membranes, bleaching of hair</p>
<p><b>Rare</b> (0.01% to 0.1%): Attacks of psoriasis</p>
<p><b>Very rare</b> (less than 0.01%): Dermatitis bullous eruptions, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, photosensitivity, exfoliative dermatitis, acute generalized exanthematous pustulosis (AGEP)</p>
<p><b>Frequency not reported</b>: Urticaria, angioedema</p>
<p><b>Postmarketing reports</b>: Hair color changes<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia</p>
<p><b>Rare</b> (0.01% to 0.1%): Exacerbation/precipitation of porphyria</p>
<p><b>Postmarketing reports</b>: Hypoglycemia, decreased appetite, porphyria<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p>
<p><b>Uncommon</b> (0.1% to 1%): Dizziness, nerve deafness, vertigo, tinnitus</p>
<p><b>Rare</b> (0.01% to 0.1%): Seizure/convulsions, neuromyopathy</p>
<p><b>Very rare</b> (less than 0.01%): Nystagmus, ataxia</p>
<p><b>Frequency not reported</b>: Hearing loss</p>
<p><b>Postmarketing reports</b>: Extrapyramidal disorders (e.g., dystonia, dyskinesia, tremor), deafness<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Affect/emotional lability</p>
<p><b>Uncommon</b> (0.1% to 1%): Nervousness</p>
<p><b>Very rare</b> (less than 0.01%): Psychosis, suicidal behavior, nightmares</p>
<p><b>Postmarketing reports</b>: Irritability<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Abnormal liver function tests</p>
<p><b>Very rare</b> (less than 0.01%): Fulminant hepatitis</p>
<p><b>Postmarketing reports</b>: Acute/fulminant hepatic failure<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Sensorimotor disorders</p>
<p><b>Frequency not reported</b>: Absent/hypoactive deep tendon reflexes</p>
<p><b>Postmarketing reports</b>: Skeletal muscle myopathy/muscle weakness/neuromyopathy (leading to progressive weakness, atrophy of proximal muscle groups), depression of tendon reflexes, abnormal nerve conduction studies<sup>[Ref]</sup></p><p>Myopathy has been reversible after therapy discontinuation, but recovery has taken many months.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (0.01% to 0.1%): Bone-marrow failure/depression, anemia, aplastic anemia, leukopenia, thrombocytopenia</p>
<p><b>Very rare</b> (less than 0.01%): Agranulocytosis</p>
<p><b>Postmarketing reports</b>: Hemolysis (in glucose-6-phosphate dehydrogenase deficient patients)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very rare</b> (less than 0.01%): Weight decreased/loss, fatigue/lassitude<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Postmarketing reports</b>: Bronchospasm<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Allergic reactions (urticaria, angioedema, bronchospasm), hypersensitivity myocarditis<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine)." Prasco Laboratories, Cincinnati, OH. </p><p id="ref_2">2. "Product Information. Plaquenil (R). (hydroxychloroquine)." Sanofi Winthrop Pharmaceuticals, New York, NY. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>An Update: Is hydroxychloroquine effective for COVID-19?</li>
<li>Does hydroxychloroquine cause emotional lability?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about hydroxychloroquine</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>296 Reviews</li>
<li>Drug class: antimalarial quinolines</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Hydroxychloroquine &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Plaquenil</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Lyme Disease, Arthritis</li>
<li>Dermatomyositis</li>
<li>Malaria</li>
<li>Malaria Prevention</li>
<li data-more-config-id="list-data-resources-conditions">... +4 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to hydroxychloroquine: compounding powder, oral tablet</i></p><h3>Cardiovascular</h3><p>QT interval prolongation has been reported in patients with specific risk factors, which may lead to arrhythmia (torsade de pointes, ventricular tachycardia).<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Cardiomyopathy (sometimes resulting in cardiac failure; some with fatal outcome), conduction disorders (bundle branch block/atrioventricular heart block), biventricular hypertrophy</p><p><b>Frequency not reported</b>: Arrhythmia (torsade de pointes, ventricular tachycardia)</p><p><b>Postmarketing reports</b>: QT interval prolongation, ventricular arrhythmias, torsade de pointes<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision (including due to disturbance of accommodation)</p><p><b>Uncommon</b> (0.1% to 1%): Retinopathy (with changes in pigmentation, visual field defects), retinal changes (including paracentral, pericentral ring types, temporal scotomas, abnormal color vision), corneal changes (including edema, opacities), haloes, photophobia</p><p><b>Very rare</b> (less than 0.01%): Extraocular muscle palsies</p><p><b>Frequency not reported</b>: Maculopathies, macular degeneration, abnormal macular pigmentation and depigmentation (sometimes with bull's eye appearance), pallor of optic disc, optic atrophy, narrowing of retinal arterioles</p><p><b>Postmarketing reports</b>: Irreversible retinopathy with retinal pigmentation changes (bull's eye appearance), visual field defects (paracentral scotomas), visual disturbances (visual acuity), maculopathies (macular degeneration), decreased dark adaptation, color vision abnormalities, corneal changes (edema, opacities), corneal deposition of drug with or without accompanying symptoms (halo around lights, photophobia, blurred vision<sup>[Ref]</sup></p><p>Blurred vision (temporary) and extraocular muscle palsies (reversible) were due to disturbance of accommodation, which was dose dependent and reversible.</p><p></p><p>Retinopathy appeared to be uncommon when the recommended daily dose was not exceeded.  In its early form, it appeared reversible when therapy was discontinued.  If allowed to develop, there was risk of progression even after treatment withdrawal.</p><p></p><p>Patients with retinal changes were asymptomatic initially or had scotomatous vision with paracentral, pericentral ring types, temporal scotomas, and abnormal color vision.</p><p></p><p>Corneal changes (including edema and opacities) have occurred from 3 weeks (infrequently) to some years after starting therapy.  They were either symptomless or caused disturbances such as haloes, blurred vision, or photophobia; they may be transient and were reversible when therapy was discontinued.</p><p></p><p>Maculopathies and macular degeneration have been reported (onset ranging from 3 months to several years of exposure to this drug) and may be irreversible.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain, nausea</p><p><b>Common</b> (1% to 10%): Diarrhea, vomiting<sup>[Ref]</sup></p><p>In general, abdominal pain, nausea, diarrhea, and vomiting resolved immediately when the dose was reduced or therapy was stopped.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>In general, skin rash, pruritus, pigmentation disorders in skin and mucous membranes, bleaching of hair, and alopecia resolved readily when therapy was discontinued.</p><p></p><p>AGEP had to be distinguished from psoriasis, although this drug has precipitated attacks of psoriasis.  AGEP has been associated with fever and hyperleukocytosis.  In general, outcome was favorable after stopping this drug.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Skin rash, pruritus, alopecia</p><p><b>Uncommon</b> (0.1% to 1%): Pigmentary changes, pigmentation disorders in skin and mucous membranes, bleaching of hair</p><p><b>Rare</b> (0.01% to 0.1%): Attacks of psoriasis</p><p><b>Very rare</b> (less than 0.01%): Dermatitis bullous eruptions, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, photosensitivity, exfoliative dermatitis, acute generalized exanthematous pustulosis (AGEP)</p><p><b>Frequency not reported</b>: Urticaria, angioedema</p><p><b>Postmarketing reports</b>: Hair color changes<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia</p><p><b>Rare</b> (0.01% to 0.1%): Exacerbation/precipitation of porphyria</p><p><b>Postmarketing reports</b>: Hypoglycemia, decreased appetite, porphyria<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p><p><b>Uncommon</b> (0.1% to 1%): Dizziness, nerve deafness, vertigo, tinnitus</p><p><b>Rare</b> (0.01% to 0.1%): Seizure/convulsions, neuromyopathy</p><p><b>Very rare</b> (less than 0.01%): Nystagmus, ataxia</p><p><b>Frequency not reported</b>: Hearing loss</p><p><b>Postmarketing reports</b>: Extrapyramidal disorders (e.g., dystonia, dyskinesia, tremor), deafness<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Affect/emotional lability</p><p><b>Uncommon</b> (0.1% to 1%): Nervousness</p><p><b>Very rare</b> (less than 0.01%): Psychosis, suicidal behavior, nightmares</p><p><b>Postmarketing reports</b>: Irritability<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Abnormal liver function tests</p><p><b>Very rare</b> (less than 0.01%): Fulminant hepatitis</p><p><b>Postmarketing reports</b>: Acute/fulminant hepatic failure<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Sensorimotor disorders</p><p><b>Frequency not reported</b>: Absent/hypoactive deep tendon reflexes</p><p><b>Postmarketing reports</b>: Skeletal muscle myopathy/muscle weakness/neuromyopathy (leading to progressive weakness, atrophy of proximal muscle groups), depression of tendon reflexes, abnormal nerve conduction studies<sup>[Ref]</sup></p><p>Myopathy has been reversible after therapy discontinuation, but recovery has taken many months.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (0.01% to 0.1%): Bone-marrow failure/depression, anemia, aplastic anemia, leukopenia, thrombocytopenia</p><p><b>Very rare</b> (less than 0.01%): Agranulocytosis</p><p><b>Postmarketing reports</b>: Hemolysis (in glucose-6-phosphate dehydrogenase deficient patients)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very rare</b> (less than 0.01%): Weight decreased/loss, fatigue/lassitude<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Postmarketing reports</b>: Bronchospasm<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Allergic reactions (urticaria, angioedema, bronchospasm), hypersensitivity myocarditis<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine)." Prasco Laboratories, Cincinnati, OH. </p><p id="ref_2">2. "Product Information. Plaquenil (R). (hydroxychloroquine)." Sanofi Winthrop Pharmaceuticals, New York, NY. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>An Update: Is hydroxychloroquine effective for COVID-19?</li>
<li>Does hydroxychloroquine cause emotional lability?</li>
</ul><h2>More about hydroxychloroquine</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>296 Reviews</li>
<li>Drug class: antimalarial quinolines</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Hydroxychloroquine &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Lyme Disease, Arthritis</li>
<li>Dermatomyositis</li>
<li>Malaria</li>
<li>Malaria Prevention</li>
<li data-more-config-id="list-data-resources-conditions">... +4 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>